Association Review
In brief
The association between C5 (Complement C5) and Atypical Hemolytic-Uremic Syndrome is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
17
Compounds
1
Trials
5of 49 via C5 compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Atypical Hemolytic-Uremic Syndrome
The disorder
7 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
13 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials
49 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
08
Provenance
References & sources
6 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access